RxDoctor Payments Data

Anthony Echols

Family · Little Rock, ARNPI 1992765457

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,919 of the $24,647 with a category attached, or 84.9%. Amgen accounts for 96.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $11,626 and has fallen 93.1% since, to $807 in 2025. Among family clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,647in general payments, 2019–2025

Across 122 payments — averaging $202.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$24K
  • Johnson & Johnson$700
  • Janssen Scientific Affairs, LLC$115
  • Stryker$80
  • Vertex$57

What the payments were for

  • Speaking & faculty fees$20,91985%
  • Travel & lodging$1,5926%
  • Food & beverage$1,9698%
  • Education$1671%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)81$23,695
Johnson & Johnson35$700
Janssen Scientific Affairs, LLC1$115
Stryker3$80
Vertex2$57

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,647 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$222,639
Medicare patients
397
Services billed
7,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$413,857
Enbrel SureclickEtanercept43$351,565
Xeljanz XrTofacitinib Citrate23$141,873
Cosentyx Sensoready PenSecukinumab19$141,717
BenlystaBelimumab12$58,110
ProliaDenosumab33$57,217
Evenity (2 Syringes)Romosozumab-Aqqg19$46,755
Hydroxychloroquine Sulfate224$7,029
MethotrexateMethotrexate Sodium232$4,587
Leflunomide68$2,996
Celecoxib53$1,276
Diclofenac Sodium20$1,003
Prednisone124$772
Sulfasalazine DrSulfasalazine39$730
Folic Acid113$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenProlia, Evenity (2 Syringes)$23,695$103,97152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →